Clinical trials: Vaccine Prophylaxis
Prevention of Meningococcal Infection
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 months of age
- Trial name
- NCT00310674
- Testing
- Meningococcal C Conjugate Vaccine
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Novartis
Yellow Fever
Trial of Yellow Fever Inactivated Vaccine
The Phase 1 trial is a single-center, randomized, double blind, placebo-controlled, dose-ranging out-patient study designed to provide the first clinical data on the safety, tolerability and immunogenicity of XRX-001 inactivated…
- Trial name
- NCT00995865
- Testing
- XRX-001 Inactivated yellow fever vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
COVID-19 Prevention
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
The purpose of this study is to demonstrate the non-inferiority (NI) of the humoral immune response of the 4 influenza vaccine strains after concomitant administration of the Ad26.COV2.S vaccine and a seasonal quadrivalent…
- Trial name
- NCT05091307
- Testing
- Ad26.COV2.S, Influenza Vaccine
- Where
- 31 sites in United States, Belgium and 1 more
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Exposure to Hepatitis B Virus
Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
There is a need for more effective and better-tolerated hepatitis B vaccines for low responder high-risk populations including patients with renal impairment and/or diabetes mellitus and those aged over 40 years.
- Trial name
- NCT01951677
- Testing
- HBsAg, PreS HBsAg, Advax-1(TM)
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Influenza, Healthy
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
This study is being conducted to compare the immunogenicity, safety, and viral shedding of a new A/H1N1 strain that will be incorporated into the FluMist quadrivalent formulation for the 2017-2018 influenza season with the…
- Trial name
- FluMist (NCT03143101)
- Testing
- FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
- Where
- 12 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Mortality, Morbidity
Sex-Differential Health Interventions In Low-Birth-Weight Infants
Our group has consistently found that the major interventions to reduce morbidity and mortality in low-income countries have sex-differential effects.
- Conditions
- Mortality, Morbidity, Growth, Neonatal Mortality
- Trial name
- NCT00625482
- Testing
- OPV, OPV plus BCG
- Where
- Guinea-Bissau
- Sponsor
- Bandim Health Project
Neisseria Gonorrheae Infection
Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men
This is a Phase 3, double-blinded, randomised placebo-controlled, multi-centred trial evaluating the efficacy of the four-component meningococcal B vaccine, 4CMenB (Bexsero®), in the prevention of Neisseria gonorrhoeae…
- Trial name
- GoGoVax (NCT04415424)
- Testing
- 4CMenB vaccine
- Where
- 7 sites in Australia
- Volunteers
- 650 people
- Sponsor
- Kirby Institute
MERS (Middle East Respiratory Syndrome), MERS
Study of Safety and Immunogenicity of BVRS-GamVac-Combi
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak.
- Trial name
- NCT04128059
- Testing
- BVRS-GamVac-Combi
- Where
- Russia
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Influenza, COVID-19
Patient-Centered Practical Vaccine Talk For Busy Clinicians
The goal of this study is to assess the effect of an educational intervention for primary care providers (PCPs) on influenza and COVID-19 vaccine uptake among their adult patients through a pragmatic, cluster randomized trial in…
- Trial name
- PCP-VAX (NCT07651761)
- Testing
- Provider communication training
- Where
- United States
- Volunteers
- 24,500 people
- Sponsor
- University of Massachusetts, Worcester
Hantaan Virus Nephropathy, Puumala Virus Nephropathy
Safety/Immunogenicity Hantaan Virus DNA Vaccine and Puumala Virus DNA Vaccine, For Prevention of HFRS
A randomized 4 cohort study that is comparing the data collected during the earlier phase study and to determine if immunogenicity can be retained with a 1 mg dose of Hantaan DNA vaccine.
- Trial name
- NCT04333459
- Testing
- Hantaan DNA Vaccine/Puumala DNA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Healthy Volunteers
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study. The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to…
- Trial name
- NCT05608005
- Testing
- Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
- Where
- 16 sites in United States
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Breast Cancer With Low to Intermediate HER2 Expression
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Purpose of this trial: 1. To assess the efficacy and safety of NeuVax™ administered with adjuvant Leukine® (sargramostim, GM-CSF). 2. To evaluate and compare the disease free survival (DFS) in the vaccinated and control subjects.
- Trial name
- PRESENT (NCT01479244)
- Testing
- NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection
- Where
- 197 sites in United States, Bulgaria and 11 more
- Volunteers
- 758 people
- Sponsor
- Galena Biopharma, Inc.
Meningococcal Disease, Infections, Meningococcal
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.
This study was designed to conduct a comparative trial to further evaluate the safety, immunogenicity and antibody persistence of two doses of Novartis MenACWY conjugate vaccine, given 2 months apart, versus one dose of Novartis…
- Trial name
- NCT01682876
- Testing
- MenACWY-CRM
- Where
- 19 sites in United States
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Influenza Vaccine Trial in HIV Uninfected Pregnant Women
Randomised, double blind, placebo controlled trial to assess safety, immunogenicity and efficacy of Trivalent Influenza vaccine in HIV uninfected pregnant women
- Trial name
- MatfluHIVneg (NCT01306669)
- Testing
- Trivalent influenza vaccine, Normal saline
- Where
- South Africa
- Volunteers
- 2,116 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults
This is a Phase I randomized, double blind, placebo controlled trial in up to 25 males and non-pregnant females, 18-45 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03473002
- Testing
- SeVRSV Vaccine
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Omicron Variants
REAl LIfe" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients
A weak immune response to two doses of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed in immunocompromised patients, including solid organ transplant recipients (SOTRs)1,2,3.
- Trial name
- NCT07473986
- Testing
- Evusheld, Control
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Vaccines, Pneumococcal, Infant
Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa
The purpose of the study is to determine whether prophylactic antipyretic treatment after vaccination with Prevenar and a concomitant hexavalent DTPa combination vaccine reduces the rate of febrile reactions.
- Conditions
- Vaccines, Pneumococcal, Infant, Fever, Chemically Induced, Drug Therapy, Combination
- Trial name
- NCT00294294
- Testing
- Prevenar, Infanrix hexa
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease, Alzheimer Disease (AD)
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention
- Trial name
- NCT06831812
- Testing
- AV-1959R (Abeta vaccine)
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Rabies
Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules
This study was planned to establish the non-inferiority of Rabipur administered as simulated post exposure Zagreb schedule as compared to Essen schedule, in healthy Indian adult subjects.
- Trial name
- NCT01365494
- Testing
- Purified Chick Embryo Cell Inactivated Rabies Vaccine
- Where
- 3 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines